NO310177B1 - Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler - Google Patents

Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler Download PDF

Info

Publication number: NO310177B1
Authority: NO; Norway
Prior art keywords: active substance; agents; aqueous; polyethylene glycol; biodegradable polymer
Prior art date: 1997-10-23

Application number

NO20002039A

Other languages

English (en)

Norwegian (no)

Other versions

NO20002039D0 (no

NO20002039L (no

Inventor

Timo Laakso

Mats Reslow

Original Assignee

Bioglan Therapeutics Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-23

Filing date

2000-04-18

Publication date

2001-06-05

2000-04-18 Application filed by Bioglan Therapeutics Ab filed Critical Bioglan Therapeutics Ab

2000-04-18 Publication of NO20002039D0 publication Critical patent/NO20002039D0/no

2000-06-13 Publication of NO20002039L publication Critical patent/NO20002039L/no

2001-06-05 Publication of NO310177B1 publication Critical patent/NO310177B1/no

Links

238000000034 method Methods 0.000 title claims abstract description 80
239000013543 active substance Substances 0.000 title claims abstract description 48
239000011859 microparticle Substances 0.000 title claims abstract description 32
239000002105 nanoparticle Substances 0.000 title claims abstract description 14
238000013268 sustained release Methods 0.000 title claims abstract description 12
239000012730 sustained-release form Substances 0.000 title claims abstract description 12
230000008569 process Effects 0.000 title claims description 9
239000002245 particle Substances 0.000 claims abstract description 50
229920001223 polyethylene glycol Polymers 0.000 claims abstract description 45
239000002202 Polyethylene glycol Substances 0.000 claims abstract description 43
229920002988 biodegradable polymer Polymers 0.000 claims abstract description 23
239000004621 biodegradable polymer Substances 0.000 claims abstract description 23
239000003960 organic solvent Substances 0.000 claims abstract description 23
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 21
239000012071 phase Substances 0.000 claims abstract description 19
238000005538 encapsulation Methods 0.000 claims abstract description 16
239000000839 emulsion Substances 0.000 claims abstract description 14
239000006185 dispersion Substances 0.000 claims abstract description 11
239000008346 aqueous phase Substances 0.000 claims abstract description 10
239000003125 aqueous solvent Substances 0.000 claims abstract description 5
230000001804 emulsifying effect Effects 0.000 claims abstract description 4
239000004005 microsphere Substances 0.000 claims description 34
229940079593 drug Drugs 0.000 claims description 32
239000003814 drug Substances 0.000 claims description 32
239000000243 solution Substances 0.000 claims description 29
102000004169 proteins and genes Human genes 0.000 claims description 19
108090000623 proteins and genes Proteins 0.000 claims description 19
239000000203 mixture Substances 0.000 claims description 16
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 15
239000000126 substance Substances 0.000 claims description 14
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims description 12
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 12
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 12
239000003795 chemical substances by application Substances 0.000 claims description 11
108090000765 processed proteins & peptides Proteins 0.000 claims description 10
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
102000004196 processed proteins & peptides Human genes 0.000 claims description 8
238000003756 stirring Methods 0.000 claims description 8
239000007864 aqueous solution Substances 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 6
102000004877 Insulin Human genes 0.000 claims description 6
108090001061 Insulin Proteins 0.000 claims description 6
238000005119 centrifugation Methods 0.000 claims description 6
229940125396 insulin Drugs 0.000 claims description 6
239000004310 lactic acid Substances 0.000 claims description 6
235000014655 lactic acid Nutrition 0.000 claims description 6
238000002156 mixing Methods 0.000 claims description 6
239000000725 suspension Substances 0.000 claims description 5
229940061720 alpha hydroxy acid Drugs 0.000 claims description 4
150000001280 alpha hydroxy acids Chemical class 0.000 claims description 4
229940088623 biologically active substance Drugs 0.000 claims description 4
229920001577 copolymer Polymers 0.000 claims description 4
238000001914 filtration Methods 0.000 claims description 4
238000001035 drying Methods 0.000 claims description 3
230000002685 pulmonary effect Effects 0.000 claims description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 2
102400001368 Epidermal growth factor Human genes 0.000 claims description 2
101800003838 Epidermal growth factor Proteins 0.000 claims description 2
102000003951 Erythropoietin Human genes 0.000 claims description 2
108090000394 Erythropoietin Proteins 0.000 claims description 2
102000001690 Factor VIII Human genes 0.000 claims description 2
108010054218 Factor VIII Proteins 0.000 claims description 2
108010051696 Growth Hormone Proteins 0.000 claims description 2
102000018997 Growth Hormone Human genes 0.000 claims description 2
102000014150 Interferons Human genes 0.000 claims description 2
108010050904 Interferons Proteins 0.000 claims description 2
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 claims description 2
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 claims description 2
229920003232 aliphatic polyester Polymers 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000003416 antiarrhythmic agent Substances 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000003146 anticoagulant agent Substances 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
239000003472 antidiabetic agent Substances 0.000 claims description 2
229940125708 antidiabetic agent Drugs 0.000 claims description 2
229940030225 antihemorrhagics Drugs 0.000 claims description 2
239000000739 antihistaminic agent Substances 0.000 claims description 2
229940125715 antihistaminic agent Drugs 0.000 claims description 2
229940124630 bronchodilator Drugs 0.000 claims description 2
239000000168 bronchodilator agent Substances 0.000 claims description 2
239000000496 cardiotonic agent Substances 0.000 claims description 2
239000003054 catalyst Substances 0.000 claims description 2
125000004122 cyclic group Chemical group 0.000 claims description 2
229910001873 dinitrogen Inorganic materials 0.000 claims description 2
229940116977 epidermal growth factor Drugs 0.000 claims description 2
229940105423 erythropoietin Drugs 0.000 claims description 2
229960000301 factor viii Drugs 0.000 claims description 2
239000000796 flavoring agent Substances 0.000 claims description 2
239000003205 fragrance Substances 0.000 claims description 2
238000004108 freeze drying Methods 0.000 claims description 2
XLXSAKCOAKORKW-UHFFFAOYSA-N gonadorelin Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CCCN=C(N)N)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 XLXSAKCOAKORKW-UHFFFAOYSA-N 0.000 claims description 2
239000000122 growth hormone Substances 0.000 claims description 2
239000004009 herbicide Substances 0.000 claims description 2
229940079322 interferon Drugs 0.000 claims description 2
229940035363 muscle relaxants Drugs 0.000 claims description 2
239000003158 myorelaxant agent Substances 0.000 claims description 2
239000002077 nanosphere Substances 0.000 claims description 2
239000004081 narcotic agent Substances 0.000 claims description 2
239000000575 pesticide Substances 0.000 claims description 2
239000013612 plasmid Substances 0.000 claims description 2
229920000747 poly(lactic acid) Polymers 0.000 claims description 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 2
239000000932 sedative agent Substances 0.000 claims description 2
229940125723 sedative agent Drugs 0.000 claims description 2
150000003431 steroids Chemical class 0.000 claims description 2
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
229960005486 vaccine Drugs 0.000 claims description 2
229940124549 vasodilator Drugs 0.000 claims description 2
239000003071 vasodilator agent Substances 0.000 claims description 2
239000002775 capsule Substances 0.000 claims 2
238000000265 homogenisation Methods 0.000 claims 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims 1
102000015696 Interleukins Human genes 0.000 claims 1
108010063738 Interleukins Proteins 0.000 claims 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
229920000954 Polyglycolide Polymers 0.000 claims 1
239000002246 antineoplastic agent Substances 0.000 claims 1
239000012736 aqueous medium Substances 0.000 claims 1
238000004140 cleaning Methods 0.000 claims 1
235000013355 food flavoring agent Nutrition 0.000 claims 1
239000002874 hemostatic agent Substances 0.000 claims 1
230000002363 herbicidal effect Effects 0.000 claims 1
239000002773 nucleotide Substances 0.000 claims 1
125000003729 nucleotide group Chemical group 0.000 claims 1
239000004633 polyglycolic acid Substances 0.000 claims 1
239000004626 polylactic acid Substances 0.000 claims 1
239000008384 inner phase Substances 0.000 abstract 1
229920000642 polymer Polymers 0.000 description 34
108091003079 Bovine Serum Albumin Proteins 0.000 description 29
229940098773 bovine serum albumin Drugs 0.000 description 29
238000002360 preparation method Methods 0.000 description 15
-1 poly(lactic acid) Polymers 0.000 description 14
239000002904 solvent Substances 0.000 description 12
239000004372 Polyvinyl alcohol Substances 0.000 description 9
229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 9
229920002451 polyvinyl alcohol Polymers 0.000 description 9
238000012360 testing method Methods 0.000 description 8
239000004815 dispersion polymer Substances 0.000 description 7
238000004519 manufacturing process Methods 0.000 description 7
238000000338 in vitro Methods 0.000 description 6
238000002347 injection Methods 0.000 description 6
239000007924 injection Substances 0.000 description 6
239000000463 material Substances 0.000 description 6
239000003995 emulsifying agent Substances 0.000 description 5
239000003094 microcapsule Substances 0.000 description 5
239000008385 outer phase Substances 0.000 description 5
229920001184 polypeptide Polymers 0.000 description 5
238000000935 solvent evaporation Methods 0.000 description 5
IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 4
108010050144 Triptorelin Pamoate Proteins 0.000 description 4
239000011149 active material Substances 0.000 description 4
239000007764 o/w emulsion Substances 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
239000001488 sodium phosphate Substances 0.000 description 4
229910000162 sodium phosphate Inorganic materials 0.000 description 4
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 3
102000008192 Lactoglobulins Human genes 0.000 description 3
108010060630 Lactoglobulins Proteins 0.000 description 3
229920003171 Poly (ethylene oxide) Polymers 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
230000015572 biosynthetic process Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000013270 controlled release Methods 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000012528 membrane Substances 0.000 description 3
229910052751 metal Inorganic materials 0.000 description 3
239000002184 metal Substances 0.000 description 3
150000002739 metals Chemical class 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
238000005507 spraying Methods 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 3
229960004824 triptorelin Drugs 0.000 description 3
239000007762 w/o emulsion Substances 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000012620 biological material Substances 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
229960004281 desmopressin Drugs 0.000 description 2
NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
238000009826 distribution Methods 0.000 description 2
238000004945 emulsification Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
239000002502 liposome Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
239000003921 oil Substances 0.000 description 2
235000019198 oils Nutrition 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000000825 pharmaceutical preparation Substances 0.000 description 2
238000005191 phase separation Methods 0.000 description 2
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
229920000053 polysorbate 80 Polymers 0.000 description 2
239000011148 porous material Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000001694 spray drying Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000005406 washing Methods 0.000 description 2
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 description 1
WHBMMWSBFZVSSR-GSVOUGTGSA-M (R)-3-hydroxybutyrate Chemical compound C[C@@H](O)CC([O-])=O WHBMMWSBFZVSSR-GSVOUGTGSA-M 0.000 description 1
FIEYHAAMDAPVCH-UHFFFAOYSA-N 2-methyl-1h-quinazolin-4-one Chemical compound C1=CC=C2NC(C)=NC(=O)C2=C1 FIEYHAAMDAPVCH-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
102000055006 Calcitonin Human genes 0.000 description 1
108060001064 Calcitonin Proteins 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
241001082241 Lythrum hyssopifolia Species 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
BCKXLBQYZLBQEK-KVVVOXFISA-M Sodium oleate Chemical compound [Na+].CCCCCCCC\C=C/CCCCCCCC([O-])=O BCKXLBQYZLBQEK-KVVVOXFISA-M 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
238000005054 agglomeration Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
150000001335 aliphatic alkanes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000000043 antiallergic agent Substances 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
239000012062 aqueous buffer Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
238000012742 biochemical analysis Methods 0.000 description 1
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
229960004015 calcitonin Drugs 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
231100000357 carcinogen Toxicity 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000003183 carcinogenic agent Substances 0.000 description 1
230000003177 cardiotonic effect Effects 0.000 description 1
230000007910 cell fusion Effects 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
239000006184 cosolvent Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229910021641 deionized water Inorganic materials 0.000 description 1
229960002845 desmopressin acetate Drugs 0.000 description 1
238000011161 development Methods 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
239000013020 final formulation Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
230000000025 haemostatic effect Effects 0.000 description 1
230000036541 health Effects 0.000 description 1
229940094991 herring sperm dna Drugs 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000006698 induction Effects 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
230000016507 interphase Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
238000005192 partition Methods 0.000 description 1
230000007170 pathology Effects 0.000 description 1
230000000737 periodic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
229920001308 poly(aminoacid) Polymers 0.000 description 1
229920000515 polycarbonate Polymers 0.000 description 1
239000004417 polycarbonate Substances 0.000 description 1
229920002721 polycyanoacrylate Polymers 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
229920006149 polyester-amide block copolymer Polymers 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
229940068968 polysorbate 80 Drugs 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
238000000746 purification Methods 0.000 description 1
238000010008 shearing Methods 0.000 description 1
229920002545 silicone oil Polymers 0.000 description 1
238000005549 size reduction Methods 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011343 solid material Substances 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
230000003068 static effect Effects 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000375 suspending agent Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
238000010998 test method Methods 0.000 description 1
229960000294 triptorelin pamoate Drugs 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
- B01J13/02—Making microcapsules or microballoons
- B01J13/06—Making microcapsules or microballoons by phase separation
- B01J13/14—Polymerisation; cross-linking
- B01J13/18—In situ polymerisation with all reactants being present in the same phase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
Nanotechnology (AREA)
Dispersion Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Crystallography & Structural Chemistry (AREA)
Manufacturing & Machinery (AREA)
Medicinal Preparation (AREA)
Manufacturing Of Micro-Capsules (AREA)
Encapsulation Of And Coatings For Semiconductor Or Solid State Devices (AREA)
Formation And Processing Of Food Products (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Glass Compositions (AREA)
Extrusion Moulding Of Plastics Or The Like (AREA)
Surgical Instruments (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Crystals, And After-Treatments Of Crystals (AREA)
Medicines Containing Plant Substances (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

NO20002039A 1997-10-23 2000-04-18 Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler NO310177B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9703874A SE512663C2 (sv)	1997-10-23	1997-10-23	Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
PCT/SE1998/001717 WO1999020253A1 (fr)	1997-10-23	1998-09-24	Procede d'encapsulage

Publications (3)

Publication Number	Publication Date
NO20002039D0 NO20002039D0 (no)	2000-04-18
NO20002039L NO20002039L (no)	2000-06-13
NO310177B1 true NO310177B1 (no)	2001-06-05

Family

ID=20408722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20002039A NO310177B1 (no)	1997-10-23	2000-04-18	Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler

Country Status (19)

Country	Link
US (1)	US6861064B1 (fr)
EP (1)	EP1033973B1 (fr)
JP (1)	JP2001520186A (fr)
KR (1)	KR100572711B1 (fr)
AT (1)	ATE249813T1 (fr)
AU (1)	AU732891B2 (fr)
CA (1)	CA2306824C (fr)
CZ (1)	CZ299100B6 (fr)
DE (1)	DE69818295T2 (fr)
DK (1)	DK1033973T3 (fr)
ES (1)	ES2205551T3 (fr)
HK (1)	HK1029931A1 (fr)
HU (1)	HU224008B1 (fr)
IL (1)	IL135733A (fr)
NO (1)	NO310177B1 (fr)
PT (1)	PT1033973E (fr)
SE (1)	SE512663C2 (fr)
WO (1)	WO1999020253A1 (fr)
ZA (1)	ZA989199B (fr)

Families Citing this family (317)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ293764B6 (cs)	1993-11-19	2004-07-14	Janssen Pharmaceutica N. V.	Farmaceutický prostředek s dostatečným a dlouhodobým uvolňováním léčiva, biodegradovatelné a biokompatibilní mikročástice, způsob jejich výroby a použití
DE19545257A1 (de)	1995-11-24	1997-06-19	Schering Ag	Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
KR20010002589A (ko) *	1999-06-16	2001-01-15	김윤	생리활성물질 함유 생분해성 고분자 마이크로스피어의 제조방법
US6458387B1 (en) *	1999-10-18	2002-10-01	Epic Therapeutics, Inc.	Sustained release microspheres
US7229619B1 (en)	2000-11-28	2007-06-12	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
IT1318539B1 (it) *	2000-05-26	2003-08-27	Italfarmaco Spa	Composizioni farmaceutiche a rilascio prolungato per lasomministrazione parenterale di sostanze idrofile biologicamente
SE517421C2 (sv)	2000-10-06	2002-06-04	Bioglan Ab	Mikropartiklar, lämpade för parenteral administration, väsentligen bestående av stärkelse med minst 85 % amylopektin och med reducerad molekylvikt, samt framställning därav
ATE409465T1 (de)	2000-10-06	2008-10-15	Pacira Pharmaceuticals Inc	Parenteral verabreichbare mikropartikel- zubereitung mit kontrollierter freisetzung
SE517422C2 (sv)	2000-10-06	2002-06-04	Bioglan Ab	Farmaceutiskt acceptabel stärkelse
EP1322291A1 (fr) *	2000-10-06	2003-07-02	Jagotec Ag	Microparticules biodegradables pour administration a liberation controlee, avec amidon a base d'amylopectine purifie de faible poids moleculaire
ATE430558T1 (de)	2000-10-27	2009-05-15	Baxter Healthcare Sa	Herstellung von mikrokügelchen
SE518007C2 (sv)	2000-11-16	2002-08-13	Bioglan Ab	Förfarande för framställning av mikropartiklar
EP1333815A1 (fr) *	2000-11-16	2003-08-13	Jagotec Ag	Procede de production de microparticules
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en)	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US6818216B2 (en)	2000-11-28	2004-11-16	Medimmune, Inc.	Anti-RSV antibodies
CA2430039C (fr)	2000-11-28	2014-01-28	Medimmune, Inc.	Procedes d'administration / de dosage d'anticorps anti-rsv destines a la prevention et au traitement
KR100676266B1 (ko) *	2000-12-08	2007-01-30	주식회사 엘지생활건강	인체 세정 조성물 내에서 마이크로 스피어의 제조방법,마이크로 스피어 및 이를 함유하는 세정 조성물
DK1355919T3 (da)	2000-12-12	2011-03-14	Medimmune Llc	Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
US7252842B2 (en)	2000-12-21	2007-08-07	Alrise Biosystems Gmbh	Induced phase transition method for the production of microparticles containing hydrophilic active agents
JP4986370B2 (ja)	2000-12-22	2012-07-25	マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ	Ｒｇｍおよびそのモジュレーターの用途
WO2002058671A1 (fr) *	2001-01-26	2002-08-01	Debio Recherche Pharmaceutique S.A.	Microparticules pharmaceutiques exemptes d"eclatement
US20080026068A1 (en) *	2001-08-16	2008-01-31	Baxter Healthcare S.A.	Pulmonary delivery of spherical insulin microparticles
ATE395042T1 (de) *	2001-08-16	2008-05-15	Baxter Int	Darreichungsformen welche mikropartikel und treibgas enthalten
US7105181B2 (en)	2001-10-05	2006-09-12	Jagotec, Ag	Microparticles
KR100560068B1 (ko) *	2002-03-14	2006-03-13	주식회사 태평양	구강용 마이크로 캡슐의 제조방법 및 이 방법에 의해 제조된 마이크로 캡슐을 함유하는 구강용 조성물
SE0201599D0 (sv)	2002-03-21	2002-05-30	Skyepharma Ab	Microparticles
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7425618B2 (en)	2002-06-14	2008-09-16	Medimmune, Inc.	Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
ES2381617T5 (es)	2002-08-14	2016-02-24	Macrogenics, Inc.	Anticuerpos específicos frente a FcgammaRIIB y sus procedimientos de uso
NZ563328A (en)	2002-10-16	2009-08-28	Euro Celtique Sa	Antibodies that bind cell-associated CA 125/0772P and methods of use thereof
JP4723859B2 (ja) *	2002-12-04	2011-07-13	日本曹達株式会社	Ｏｉｌ／Ｏｉｌ液中乾燥法による農薬マイクロカプセル製剤及びその製造方法
KR20110120989A (ko)	2003-01-06	2011-11-04	코릭사 코포레이션	특정의 아미노알킬 글루코사미나이드 포스페이트 화합물 및 그들의 용도
US7960522B2 (en)	2003-01-06	2011-06-14	Corixa Corporation	Certain aminoalkyl glucosaminide phosphate compounds and their use
ES2897506T3 (es)	2003-01-09	2022-03-01	Macrogenics Inc	Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
EP2052713A3 (fr)	2003-01-13	2009-05-20	Macrogenics, Inc.	Protéines de fusion FcgammaR solubles et leurs procédés d'utilisation
DE10303974A1 (de)	2003-01-31	2004-08-05	Abbott Gmbh & Co. Kg	Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
WO2004091763A2 (fr)	2003-04-10	2004-10-28	President And Fellows Of Harvard College	Formation et regulation d'especes fluidiques
WO2004091510A2 (fr)	2003-04-11	2004-10-28	Medimmune, Inc.	Anticorps il-9 recombinants et leurs utilisations
US7326571B2 (en)	2003-07-17	2008-02-05	Boston Scientific Scimed, Inc.	Decellularized bone marrow extracellular matrix
US20070092452A1 (en) *	2003-07-18	2007-04-26	Julia Rashba-Step	Methods for fabrication, uses, compositions of inhalable spherical particles
US20050142205A1 (en) *	2003-07-18	2005-06-30	Julia Rashba-Step	Methods for encapsulating small spherical particles prepared by controlled phase separation
US8075919B2 (en) *	2003-07-18	2011-12-13	Baxter International Inc.	Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation
CA2532874A1 (fr) *	2003-07-22	2005-02-03	Baxter International Inc.	Petites particules spheriques de molecules organiques de faible poids moleculaire et procedes de preparation et d'utilisation correspondants
AU2004286198C1 (en)	2003-08-18	2011-02-24	Medimmune, Llc	Humanization of antibodies
JP4630870B2 (ja)	2003-08-27	2011-02-09	プレジデントアンドフェロウズオブハーバードカレッジ	流体種の電子的制御
JP2005138051A (ja) *	2003-11-07	2005-06-02	Kurita Water Ind Ltd	除去材の製造方法及び除去材
FR2867075B1 (fr) *	2004-03-03	2006-07-14	Ethypharm Sa	Procede de preparation de microspheres biodegradables calibrees
US8728525B2 (en) *	2004-05-12	2014-05-20	Baxter International Inc.	Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
JP5634009B2 (ja)	2004-05-12	2014-12-03	バクスター・インターナショナル・インコーポレイテッドＢａｘｔｅｒＩｎｔｅｒｎａｔｉｏｎａｌＩｎｃｏｒｐ０Ｒａｔｅｄ	タンパク質を含み、そして高濃度のタンパク質で注射性能を示すミクロスフェア
US7884085B2 (en) *	2004-05-12	2011-02-08	Baxter International Inc.	Delivery of AS-oligonucleotide microspheres to induce dendritic cell tolerance for the treatment of autoimmune type 1 diabetes
DK2072040T3 (da) *	2004-05-12	2013-07-29	Baxter Healthcare Sa	Terapeutisk anvendelse af nukleinsyremikrokugler
EP1778268B1 (fr)	2004-07-21	2016-05-04	Tulane University Health Sciences Center	Traitement du dysfonctionnement renal et du myelome multiple a l'aide de composes pacap
EP3073267A1 (fr)	2004-09-21	2016-09-28	Medimmune, Inc.	Anticorps dirigés contre et procédés de production de vaccins pour virus respiratoire syncytial
WO2006047639A2 (fr)	2004-10-27	2006-05-04	Medimmune, Inc.	Modulation d'une specificite d'anticorps par adaptation sur mesure de son affinite a un antigene apparente
JP5175107B2 (ja) *	2005-02-11	2013-04-03	ノーラブズエービー	酸化窒素による神経障害の治療デバイス、方法および使用
WO2006102095A2 (fr)	2005-03-18	2006-09-28	Medimmune, Inc.	Rearrangement de l'infrastructure d'anticorps
US9427605B2 (en)	2005-03-24	2016-08-30	Novan, Inc.	Cosmetic treatment with nitric oxide, device for performing said treatment and manufacturing method therefor
CA2605024C (fr)	2005-04-15	2018-05-22	Macrogenics, Inc.	Di-anticorps covalents et leurs utilisations
ES2272156B1 (es) *	2005-04-18	2008-04-01	Italfarmaco, S.A.	Sistemas microparticulares.
MX2007013356A (es) *	2005-04-27	2008-03-26	Baxter Int	Microparticulas modificadas en la superficie y metodos de formacion y uso de las mismas.
EP1888510A4 (fr)	2005-05-27	2013-01-16	Univ North Carolina	Particules liberant de l'oxyde nitrique pour therapie a base d'oxyde nitrique et applications biomedicales
US20070110757A1 (en)	2005-06-23	2007-05-17	Ziping Wei	Antibody formulations having optimized aggregation and fragmentation profiles
WO2007014445A1 (fr) *	2005-08-02	2007-02-08	Miv Therapeutics Inc.	Micro-dispositifs comprenant des nanocapsules pour l'administration controlee de medicaments et procede de fabrication idoine
PT2573114T (pt)	2005-08-10	2016-07-13	Macrogenics Inc	Identificação e manipulação de anticorpos com regiões fc variantes e métodos de utilização dos mesmos
TWI323734B (en)	2005-08-19	2010-04-21	Abbott Lab	Dual variable domain immunoglobulin and uses thereof
EP2500359A3 (fr)	2005-08-19	2012-10-17	Abbott Laboratories	Immunoglobuline à double domaine variable et ses utilisations
ES2542501T3 (es)	2005-09-30	2015-08-06	Abbvie Deutschland Gmbh & Co Kg	Dominios de unión de proteínas de la familia de proteínas de moléculas de orientación repulsiva (RGM) y fragmentos funcionales de las mismas, así como su uso
KR101114659B1 (ko) *	2005-10-14	2012-03-05	(주)아모레퍼시픽	생분해성 고분자를 이용하여 유용성 활성성분을 안정화한나노입자 및 이의 제조방법
RU2442793C2 (ru)	2005-11-30	2012-02-20	Эбботт Лэборетриз	АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
RU2432362C2 (ru)	2005-11-30	2011-10-27	Эбботт Лэборетриз	Моноклональные антитела и их применения
CN1799649A (zh) *	2005-12-09	2006-07-12	清华大学	一种血液相容性生物材料及其制备方法
US20070154546A1 (en) *	2005-12-30	2007-07-05	Zhang Jack Y	Sustained release pharmaceutical compositions
EP2198863A1 (fr)	2006-02-27	2010-06-23	The Johns Hopkins University	Traitement anticancéreux utilisant des inhibiteurs de gamma-sécrétases
KR100722191B1 (ko) *	2006-04-19	2007-05-29	경북대학교 산학협력단	고내구성 방향성 접착제 및 이를 이용한 서방형 방향 섬유
US20070281031A1 (en) *	2006-06-01	2007-12-06	Guohan Yang	Microparticles and methods for production thereof
CA2655080A1 (fr)	2006-06-14	2007-12-21	Macrogenics, Inc.	Procedes de traitement de troubles auto-immuns utilisant des anticorps monoclonaux a toxicite reduite
PL2029173T3 (pl)	2006-06-26	2017-04-28	Macrogenics, Inc.	Przeciwciała swoiste dla FC RIIB i sposoby ich zastosowania
MX2009001226A (es)	2006-08-04	2009-03-20	Baxter Int	Composicion basada en microesferas para prevenir y/o revertir la diabetes autoinmune de nuevo inicio.
DK2292663T3 (da)	2006-08-28	2013-11-04	Kyowa Hakko Kirin Co Ltd	Antagonistiske human-let-specifikke, humane monoklonale antistoffer
ES2781402T7 (es)	2006-09-07	2021-06-09	Scott & White Memorial Hospital	Métodos y composiciones basadas en conjugados de toxina diftérica-interleucina-3
CN101512008B (zh)	2006-09-08	2015-04-01	艾伯维巴哈马有限公司	白介素-13结合蛋白
AU2007319577A1 (en) *	2006-10-06	2008-05-22	Baxter Healthcare S.A.	Microencapsules containing surface-modified microparticles and methods of forming and using the same
WO2008048545A2 (fr)	2006-10-16	2008-04-24	Medimmune, Llc.	Molécules ayant des demi-vies réduites, compositions et leurs utilisations
US8455626B2 (en)	2006-11-30	2013-06-04	Abbott Laboratories	Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008104386A2 (fr)	2007-02-27	2008-09-04	Abbott Gmbh & Co. Kg	Méthode de traitement d'amyloïdoses
RU2422134C1 (ru) *	2007-04-19	2011-06-27	Донг-А Фармасьютикал. Ко., Лтд	Композиция биоразлагающихся микросфер, пригодная для контролируемого высвобождения контролирующего уровень глюкозы пептида, и ее состав
EP1997830A1 (fr)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	Molécules à liaison spécifiques RSV et leur moyen de fabrication
CN107226864A (zh)	2007-06-21	2017-10-03	宏观基因有限公司	共价双抗体及其用途
EP2626371A1 (fr)	2007-07-31	2013-08-14	MedImmune, LLC	Protéines de liaison d'épitope multispécifique et leurs utilisations
US20110033378A1 (en)	2008-01-18	2011-02-10	Medlmmune, Llc.	Cysteine Engineered Antibodies For Site-Specific Conjugation
US8420088B2 (en)	2008-01-28	2013-04-16	Novartis Ag	Methods and compositions using FGF23 fusion polypeptides
TW200936156A (en)	2008-01-28	2009-09-01	Novartis Ag	Methods and compositions using Klotho-FGF fusion polypeptides
US8962803B2 (en)	2008-02-29	2015-02-24	AbbVie Deutschland GmbH & Co. KG	Antibodies against the RGM A protein and uses thereof
SG190572A1 (en)	2008-04-29	2013-06-28	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
EP2500361B1 (fr)	2008-05-09	2016-03-30	AbbVie Deutschland GmbH & Co KG	Anticorps contre le récepteur pour produits terminaux de glycation avancée (RAGE) et utilisations de ceux-ci
WO2009149189A2 (fr)	2008-06-03	2009-12-10	Abbott Laboratories	Immunoglobulines à deux domaines variables et leurs utilisations
AR072000A1 (es)	2008-06-03	2010-07-28	Abbott Lab	Proteinas de union multivalentes con capacidad de unir dos o mas antigenos y usos de la misma
TW201014602A (en)	2008-07-08	2010-04-16	Abbott Lab	Prostaglandin E2 binding proteins and uses thereof
NZ603698A (en)	2008-07-08	2014-03-28	Abbvie Inc	Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
US8323685B2 (en)	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing compositions containing microparticles
US20100047292A1 (en) *	2008-08-20	2010-02-25	Baxter International Inc.	Methods of processing microparticles and compositions produced thereby
US8323615B2 (en) *	2008-08-20	2012-12-04	Baxter International Inc.	Methods of processing multi-phasic dispersions
US8367427B2 (en) *	2008-08-20	2013-02-05	Baxter International Inc.	Methods of processing compositions containing microparticles
WO2010039865A2 (fr) *	2008-10-01	2010-04-08	Cornell University	Système biodégradable d'administration d'agent chimique
CA2999537C (fr)	2008-10-10	2021-10-19	Dana-Farber Cancer Institute	Modulateurs chimiques des polypeptides bax et bcl-2 pro-apoptotiques
CA2746256C (fr)	2008-12-09	2020-03-24	Loren D. Walensky	Procedes et compositions pour la modulation specifique de mcl-1
PL2786762T3 (pl)	2008-12-19	2019-09-30	Macrogenics, Inc.	Kowalencyjne diabody i ich zastosowania
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8030026B2 (en)	2009-02-24	2011-10-04	Abbott Laboratories	Antibodies to troponin I and methods of use thereof
NZ594514A (en)	2009-03-05	2013-06-28	Abbott Lab	Interleukin-17 BINDING PROTEINS
US8283162B2 (en)	2009-03-10	2012-10-09	Abbott Laboratories	Antibodies relating to PIVKAII and uses thereof
WO2010141329A1 (fr)	2009-06-01	2010-12-09	Medimmune, Llc	Molecules a demi-vie prolongee et utilisations associees
EP2711018A1 (fr)	2009-06-22	2014-03-26	MedImmune, LLC	Régions Fc modifiées pour conjugaison spécifique d'un site
SG178335A1 (en)	2009-08-13	2012-03-29	Crucell Holland Bv	Antibodies against human respiratory syncytial virus (rsv) and methods of use
CN102741288B (zh)	2009-08-29	2015-08-19	Abbvie公司	治疗用dll4结合蛋白
CA2772628A1 (fr)	2009-09-01	2011-03-10	Abbott Laboratories	Immunoglobulines a double domaine variable et leurs utilisations
WO2011035205A2 (fr)	2009-09-18	2011-03-24	Calmune Corporation	Anticorps dirigés contre candida, leurs collectes et procédés d'utilisation
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
PL2486141T3 (pl)	2009-10-07	2018-07-31	Macrogenics, Inc.	Polipeptydy zawierające regiony fc i mające w wyniku zmian w zakresie fukozylacji ulepszoną funkcję efektorową, i sposoby zastosowania tych polipeptydów
TW201119676A (en)	2009-10-15	2011-06-16	Abbott Lab	Dual variable domain immunoglobulins and uses thereof
UY32979A (es)	2009-10-28	2011-02-28	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
WO2011053707A1 (fr)	2009-10-31	2011-05-05	Abbott Laboratories	Anticorps pour récepteur pour produits terminaux de glycation avancée (rage) et utilisations de ceux-ci
CN102883739B (zh)	2009-11-02	2015-11-25	图兰恩教育基金管理人	垂体腺苷酸环化酶激活多肽（pacap）的类似物和它们的应用方法
BR112012013734A2 (pt)	2009-12-08	2017-01-10	Abbott Gmbh & Co Kg	anticorpos monoclonais contra a proteína rgm a para uso no tratamento da degeneração da camada de fibras nervosas da retina.
USRE49251E1 (en)	2010-01-04	2022-10-18	Mapi Pharma Ltd.	Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
JP5964249B2 (ja)	2010-03-02	2016-08-03	アッヴィ・インコーポレイテッド	治療用ｄｌｌ４結合タンパク質
MX360403B (es)	2010-04-15	2018-10-31	Abbvie Inc	Proteinas de union a amiloide beta.
KR20130066632A (ko)	2010-05-06	2013-06-20	노파르티스 아게	치료적 저밀도 지단백질-관련 단백질 ６（ｌｒｐ６） 항체에 대한 조성물 및 사용 방법
MX2012012927A (es)	2010-05-06	2013-05-01	Novartis Ag	Composiciones y metodos de uso para anticuerpos multivalentes terapeuticos de proteina relacionada con lipoproteina de baja densidad 6 (lrp6).
LT2571532T (lt)	2010-05-14	2017-08-10	Abbvie Inc.	Il-1 surišantys baltymai
WO2012006500A2 (fr)	2010-07-08	2012-01-12	Abbott Laboratories	Anticorps monoclonaux contre la protéine de capside du virus de l'hépatite c
SG186985A1 (en)	2010-07-09	2013-02-28	Crucell Holland Bv	Anti-human respiratory syncytial virus (rsv) antibodies and methods of use
UY33492A (es)	2010-07-09	2012-01-31	Abbott Lab	Inmunoglobulinas con dominio variable dual y usos de las mismas
US9120862B2 (en)	2010-07-26	2015-09-01	Abbott Laboratories	Antibodies relating to PIVKA-II and uses thereof
SG187682A1 (en)	2010-08-02	2013-03-28	Macrogenics Inc	Covalent diabodies and uses thereof
EP3252072A3 (fr)	2010-08-03	2018-03-14	AbbVie Inc.	Immunoglobuline à double domaine variable et ses utilisations
US9062101B2 (en)	2010-08-14	2015-06-23	AbbVie Deutschland GmbH & Co. KG	Amyloid-beta binding proteins
HRP20220405T1 (hr)	2010-08-19	2022-05-27	Zoetis Belgium S.A.	Protutijela protiv ngf i njihova upotreba
CN105037552B (zh)	2010-08-20	2019-03-29	诺华股份有限公司	表皮生长因子受体3（her3)的抗体
RU2013113225A (ru)	2010-08-26	2014-10-10	Эббви Инк.	Иммуноглобулины с двумя вариабельными доменами и их применение
US9757482B2 (en)	2010-08-30	2017-09-12	Hanwha Chemical Corporation	Iron oxide nanocapsules, method of manufacturing the same, and MRI contrast agent using the same
KR101642939B1 (ko) *	2010-08-31	2016-07-26	한화케미칼 주식회사	산화철 나노캡슐, 이의 제조방법 및 이를 포함하는 자기공명영상진단 조영제
US8580739B2 (en) *	2010-11-17	2013-11-12	East Carolina University	Methods of reducing myocardial injury following myocardial infarction
EP2643353A1 (fr)	2010-11-24	2013-10-02	Novartis AG	Molécules multi-spécifiques
AU2011361720B2 (en)	2010-12-21	2017-04-27	Abbvie Inc.	IL-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
WO2012088094A2 (fr)	2010-12-21	2012-06-28	Abbott Laboratories	Protéines liant l'il-1
ES2669310T3 (es)	2011-04-20	2018-05-24	Medimmune, Llc	Anticuerpos y otras moléculas que se unen con B7-H1 y PD-1
NZ618016A (en)	2011-05-21	2015-05-29	Macrogenics Inc	Deimmunized serum-binding domains and their use for extending serum half-life
BR112014000178A2 (pt)	2011-07-05	2017-02-07	Novan Inc	composições tópicas
CA2841970A1 (fr)	2011-07-13	2013-01-17	Abbvie Inc.	Methodes et compositions pour le traitement de l'asthme a l'aide d'anticorps anti-il-13
AU2012296613B2 (en)	2011-08-15	2016-05-12	Amplimmune, Inc.	Anti-B7-H4 antibodies and their uses
WO2013027191A1 (fr)	2011-08-25	2013-02-28	Novartis Ag	Procédés et compositions utilisant des polypeptides de fusion fgf23
CA2849409A1 (fr)	2011-09-23	2013-03-28	Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa	Agents du facteur de necrose tumorale alpha et utilisations de ceux-ci
DE102011114864A1 (de)	2011-10-05	2013-04-11	Acino Ag	Verfahren zur Herstellung einer homogenen Pulvermischung und Verfahren zur Herstellung eines Implantats sowie Implantat
TW201323440A (zh)	2011-10-24	2013-06-16	Abbvie Inc	抗骨硬化素（ｓｃｌｅｒｏｓｔｉｎ）之免疫結合物
US20140335135A1 (en) *	2011-12-05	2014-11-13	Ferring Bv	Pharmaceutical composition
US20130273029A1 (en)	2011-12-05	2013-10-17	Novartis Ag	Antibodies for epidermal growth factor receptor 3 (her3) directed to domain ii of her3
KR102218497B1 (ko)	2011-12-05	2021-02-22	노파르티스 아게	표피 성장 인자 수용체 3 (her3)에 대한 항체
CA2855840C (fr)	2011-12-14	2023-08-29	AbbVie Deutschland GmbH & Co. KG	Composition et methode pour le diagnostic et le traitement de troubles lies au fer
JP6336397B2 (ja)	2011-12-14	2018-06-06	アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー	鉄関連障害を診断および治療するための組成物および方法
EP3539982A3 (fr)	2011-12-23	2020-01-15	Pfizer Inc	Régions constantes d'anticorps modifiés pour conjugaison spécifique à un site, et leurs procédés et utilisations
WO2013102042A2 (fr)	2011-12-30	2013-07-04	Abbvie Inc.	Protéines à double liaison spécifique dirigées contre l'il-13 et/ou l'il-17
CN104487455A (zh)	2012-01-27	2015-04-01	艾伯维德国有限责任两合公司	用于诊断和治疗与神经突变性相关的疾病的组合物和方法
BR112014022228A2 (pt)	2012-03-08	2017-07-11	Halozyme Inc	anticorpos anti-epidérmicos de receptor de fator de crescimento condicionalmente ativo e métodos de uso dos mesmos
US9408419B2 (en)	2012-03-23	2016-08-09	Victoria's Secret Store Brand Management, Inc.	Moisturizing fabric material, use thereof in moisturizing bras, and method of manufacture
US9668974B2 (en)	2012-05-10	2017-06-06	Painreform Ltd.	Depot formulations of a local anesthetic and methods for preparation thereof
US20150104468A1 (en)	2012-06-04	2015-04-16	Irm Llc	Site-specific labeling methods and molecules produced thereby
ES2894852T3 (es)	2012-06-06	2022-02-16	Zoetis Services Llc	Anticuerpos anti-NGF caninizados y métodos de los mismos
WO2014011955A2 (fr)	2012-07-12	2014-01-16	Abbvie, Inc.	Protéines de liaison à il-1
MX2015005593A (es)	2012-11-01	2016-02-05	Abbvie Inc	Inmunoglobulinas de dominio variable dual anti-vegf/dll4 y usos de las mismas.
RU2015115956A (ru)	2012-11-09	2017-01-10	Пфайзер Инк.	Антитела, специфичные в отношении фактора роста тромбоцитов в, и их композиции и применения
JP2016505843A (ja)	2012-12-19	2016-02-25	アンプリミューン，インコーポレイテッド	Ｂ７−ｈ４特異的抗体、並びにその組成物及び使用方法
JP6359031B2 (ja)	2012-12-21	2018-07-18	メディミューン，エルエルシー	抗ｈ７ｃｒ抗体
HUE054443T2 (hu)	2013-02-08	2021-09-28	Novartis Ag	Ellenanyagok módosítására, ezáltal immunkonjugátumok elõállítására szolgáló specifikus helyek
WO2014124258A2 (fr)	2013-02-08	2014-08-14	Irm Llc	Sites spécifiques de modification d'anticorps pour fabriquer des immunoconjugués
US9855211B2 (en)	2013-02-28	2018-01-02	Novan, Inc.	Topical compositions and methods of using the same
US9498532B2 (en)	2013-03-13	2016-11-22	Novartis Ag	Antibody drug conjugates
MX2015012825A (es)	2013-03-14	2016-06-10	Abbott Lab	Anticuerpos monoclonales del dominio de union de lipido del núcleo del virus de la hepatitis c vhc.
BR112015023355A8 (pt)	2013-03-14	2018-01-30	Abbott Lab	antígenos recombinantes ns3 de hcv e mutantes dos mesmos para detecção de anticorpos aprimorada.
CN105228649B (zh)	2013-03-14	2019-01-18	雅培制药有限公司	Hcv抗原-抗体组合测定和方法以及用在其中的组合物
EP2970479B1 (fr)	2013-03-14	2019-04-24	Novartis AG	Anticorps dirigés contre notch 3
ES2701051T3 (es)	2013-03-15	2019-02-20	Novartis Ag	Conjugados de anticuerpo-fármaco
US9469686B2 (en)	2013-03-15	2016-10-18	Abbott Laboratories	Anti-GP73 monoclonal antibodies and methods of obtaining the same
AU2014227732A1 (en)	2013-03-15	2015-09-17	Abbvie Inc.	Dual specific binding proteins directed against IL-1 beta and IL-17
CN106414489A (zh)	2013-05-24	2017-02-15	米迪缪尼有限公司	抗-b7-h5抗体及其用途
SG10201708143QA (en)	2013-06-06	2017-11-29	Pierre Fabre Medicament	Anti-c10orf54 antibodies and uses thereof
EP3632467B1 (fr)	2013-06-07	2023-09-27	Duke University	Inhibiteurs de facteur h du complément
WO2016022170A1 (fr)	2014-08-08	2016-02-11	Novan, Inc.	Émulsions topiques
JP6513667B2 (ja)	2013-08-08	2019-05-15	ノヴァン，インコーポレイテッド	局所用組成物およびそれを使用する方法
US11384149B2 (en)	2013-08-09	2022-07-12	Macrogenics, Inc.	Bi-specific monovalent Fc diabodies that are capable of binding CD32B and CD79b and uses thereof
UA116479C2 (uk)	2013-08-09	2018-03-26	Макродженікс, Інк.	БІСПЕЦИФІЧНЕ МОНОВАЛЕНТНЕ Fc-ДІАТІЛО, ЯКЕ ОДНОЧАСНО ЗВ'ЯЗУЄ CD32B I CD79b, ТА ЙОГО ЗАСТОСУВАННЯ
EP2840091A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Diabody se liant specifiquement a l'antigene gpA33 et CD3 et procedes d'utilisation
EP2839842A1 (fr)	2013-08-23	2015-02-25	MacroGenics, Inc.	Bianticorps monovalents bi-spécifiques capables de se lier aux CD123 et CD3 et leurs utilisations
WO2015038984A2 (fr)	2013-09-12	2015-03-19	Halozyme, Inc.	Anticorps anti-récepteur du facteur de croissance épidermique modifiés et procédés pour les utiliser
CN105793284A (zh)	2013-09-17	2016-07-20	大学健康网络(Uhn):技术开发和商业化公司	针对顺式RGMa/再生蛋白相互作用或脂筏的试剂及其在治疗方法中的应用
WO2015058868A1 (fr)	2013-10-25	2015-04-30	Pangaea Biotech, S.L.	Compositions et procédés pour le traitement du cancer
US10287572B2 (en)	2013-11-01	2019-05-14	Regents Of The University Of Minnesota	Protein scaffolds and methods of use
CA3056647A1 (fr)	2013-11-13	2015-05-21	Robert ARCH	Anticorps specifiques du ligand 1a de type facteur de necrose tumorale et compositions ainsi qu'utilisations associees
TW201536320A (zh)	2013-12-02	2015-10-01	Abbvie Inc	治療骨性關節炎之組合物及方法
WO2015109212A1 (fr)	2014-01-17	2015-07-23	Pfizer Inc.	Anticorps anti-il-2 et compositions et utilisations de ceux-ci
EP3097122B9 (fr)	2014-01-24	2020-11-11	NGM Biopharmaceuticals, Inc.	Anticorps liant beta-klotho 2 et leurs procédés d'utilisation
CN106604740A (zh)	2014-02-14	2017-04-26	宏观基因有限公司	用于治疗血管化癌症的改进的方法
EP3450571B1 (fr)	2014-02-24	2023-04-05	Celgene Corporation	Procédés d'utilisation d'un activateur du céréblon pour l'expansion de cellules neurales et le traitement de troubles du système nerveux central
GB201403775D0 (en)	2014-03-04	2014-04-16	Kymab Ltd	Antibodies, uses & methods
WO2015138337A1 (fr)	2014-03-09	2015-09-17	Abbvie, Inc.	Compositions et méthodes de traitement d'une polyarthrite rhumatoïde
JP2017509337A (ja)	2014-03-12	2017-04-06	ノバルティスアーゲー	イムノコンジュゲートを作製する抗体を修飾するための特定部位
UA125575C2 (uk)	2014-03-21	2022-04-27	Еббві Інк.	Кон'югат, що містить антитіло проти egfr та лікарський засіб
ES2869459T3 (es)	2014-05-16	2021-10-25	Medimmune Llc	Moléculas con unión a receptor de fc de neonato alterada que tiene propiedades terapéuticas y de diagnóstico potenciadas
NZ726520A (en)	2014-05-29	2018-12-21	Macrogenics Inc	Tri-specific binding molecules that specifically bind to multiple cancer antigens and methods of use thereof
TWI693232B (zh)	2014-06-26	2020-05-11	美商宏觀基因股份有限公司	與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
CN107257691B (zh)	2014-07-16	2021-09-21	达娜-法勃肿瘤研究所公司	低级别浆液性卵巢癌中的her3抑制
WO2016020791A1 (fr)	2014-08-05	2016-02-11	Novartis Ag	Conjugués anticorps ckit-médicament
TN2016000577A1 (en)	2014-08-12	2018-04-04	Novartis Ag	Anti-cdh6 antibody drug conjugates
ES2935062T3 (es)	2014-09-26	2023-03-01	Macrogenics Inc	Diacuerpos monovalentes biespecíficos que son capaces de unirse a CD19 y CD3 y usos de los mismos
UY36401A (es)	2014-11-14	2016-06-30	Novartis Ag	Conjugados anticuerpos-fármacos
EA201791238A1 (ru)	2014-12-04	2018-02-28	Новартис Аг	Способы и композиции, в которых используются варианты полипептидов klotho
EP3229838B1 (fr)	2014-12-11	2020-09-09	Pierre Fabre Médicament	Anticorps anti-c10orf54 et leurs utilisations
US10093733B2 (en)	2014-12-11	2018-10-09	Abbvie Inc.	LRP-8 binding dual variable domain immunoglobulin proteins
US20160244520A1 (en)	2015-01-24	2016-08-25	Abbvie Inc.	Compositions and methods for treating psoriatic arthritis
US10501552B2 (en)	2015-01-26	2019-12-10	Macrogenics, Inc.	Multivalent molecules comprising DR5-binding domains
WO2016120828A1 (fr)	2015-01-30	2016-08-04	Novartis Ag	Traitement du cancer du sein par un antagoniste de m-csf
SG10201907901XA (en)	2015-03-03	2019-10-30	Kymab Ltd	Antibodies, uses & methods
KR102661078B1 (ko)	2015-05-29	2024-05-23	애브비 인코포레이티드	항-ｃｄ40 항체 및 그의 용도
TWI773646B (zh)	2015-06-08	2022-08-11	美商宏觀基因股份有限公司	結合lag-3的分子和其使用方法
TW201710286A (zh)	2015-06-15	2017-03-16	艾伯維有限公司	抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
EP3310813A1 (fr)	2015-06-17	2018-04-25	Novartis AG	Conjugués anticorps-médicament
CA3025896A1 (fr)	2015-07-23	2017-01-26	The Regents Of The University Of California	Anticorps anti-facteur de coagulation xia et leurs utilisations
IL287916B2 (en)	2015-07-30	2023-09-01	Macrogenics Inc	Molecules that bind pd-1 and methods of using them
AU2016319129A1 (en)	2015-09-11	2018-04-05	AbbVie Deutschland GmbH & Co. KG	Methods for treating relapsing forms of multiple sclerosis
US9862760B2 (en)	2015-09-16	2018-01-09	Novartis Ag	Polyomavirus neutralizing antibodies
CN108289953B (zh)	2015-09-29	2022-03-11	细胞基因公司	Pd-1结合蛋白及其使用方法
WO2017070561A1 (fr)	2015-10-23	2017-04-27	Pfizer Inc.	Anticorps anti-il-2, compositions les contenant et leurs utilisations
EP3383908A1 (fr)	2015-12-02	2018-10-10	Stsciences, Inc.	Anticorps spécifiques au btla glycosylé (atténuateur de lymphocytes b et t)
ES2861449T3 (es)	2015-12-02	2021-10-06	Stcube & Co Inc	Anticuerpos y moléculas que se unen inmunoespecíficamente a BTN1A1 y los usos terapéuticos de los mismos
US10954301B2 (en)	2015-12-14	2021-03-23	Macrogenics, Inc.	Bispecific molecules having immunoreactivity with PD-1 and CTLA-4, and methods of use thereof
MA55746A (fr)	2016-01-21	2022-03-02	Novartis Ag	Molécules multispécifiques ciblant cll-1
US10912743B2 (en)	2016-03-02	2021-02-09	Novan, Inc.	Compositions for treating inflammation and methods of treating the same
US11166980B2 (en)	2016-04-13	2021-11-09	Novan, Inc.	Compositions, systems, kits, and methods for treating an infection
WO2017192407A1 (fr)	2016-05-02	2017-11-09	Roman Bielski	Microcapsules pour l'administration contrôlée d'un principe actif pharmaceutique
AU2017277914A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-CD98 antibodies and antibody drug conjugates
JP2019526529A (ja)	2016-06-08	2019-09-19	アッヴィ・インコーポレイテッド	抗ｂ７−ｈ３抗体及び抗体薬物コンジュゲート
CR20180603A (es)	2016-06-08	2019-07-29	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y fármaco
AU2017290832B2 (en)	2016-07-01	2023-10-19	Dana-Farber Cancer Institute, Inc.	Compositions, assays, and methods for direct modulation of fatty acid metabolism
US12097292B2 (en)	2016-08-28	2024-09-24	Mapi Pharma Ltd.	Process for preparing microparticles containing glatiramer acetate
MX2019002867A (es)	2016-09-19	2019-11-12	Celgene Corp	Metodos de tratamiento de trastornos inmunologicos usando proteinas de union a pd-1.
EP3515943A4 (fr)	2016-09-19	2020-05-06	Celgene Corporation	Méthodes de traitement du vitiligo au moyen de protéines de liaison à pd-1
EP3534947A1 (fr)	2016-11-03	2019-09-11	Kymab Limited	Anticorps, combinaisons comprenant des anticorps, biomarqueurs, utilisations et procédés
EP3544628A4 (fr)	2016-11-23	2020-11-18	Immunoah Therapeutics, Inc.	Protéines de liaison à 4-1bb et leurs utilisations
JOP20190187A1 (ar)	2017-02-03	2019-08-01	Novartis Ag	مترافقات عقار جسم مضاد لـ ccr7
JP2020515530A (ja)	2017-03-26	2020-05-28	マピファーマリミテッド	進行型の多発性硬化症を治療するためのグラチラマーデポシステム
WO2018185618A1 (fr)	2017-04-03	2018-10-11	Novartis Ag	Conjugués de médicament-anticorps anti-cdh6 et combinaisons d'anticorps anti-gitr et méthodes de traitement
US11260358B2 (en) *	2017-04-17	2022-03-01	The Trustees Of The University Of Pennsylvania	Aqueous systems of at least two phases containing microcapsules and processes for manufacturing the same
US10865238B1 (en)	2017-05-05	2020-12-15	Duke University	Complement factor H antibodies
AU2018277545A1 (en)	2017-05-31	2019-12-19	Stcube & Co., Inc.	Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
EP3630835A1 (fr)	2017-05-31	2020-04-08	STCube & Co., Inc.	Anticorps et molécules se liant de manière immunospécifique à btn1a1 et leurs utilisations thérapeutiques
EP3635007A1 (fr)	2017-06-06	2020-04-15	STCube & Co., Inc.	Procédés de traitement du cancer à l'aide d'anticorps et de molécules se liant à btn1a1 ou des ligands de btn1a1
US10875915B2 (en)	2017-12-01	2020-12-29	Pfizer Inc.	Anti-CXCR5 antibodies and compositions and uses thereof
JP2021508439A (ja)	2017-12-01	2021-03-11	ノバルティスアーゲー	ポリオーマウイルス中和抗体
MX2020009526A (es)	2018-03-12	2020-10-28	Zoetis Services Llc	Anticuerpos anti-ngf y metodos de estos.
WO2019190984A1 (fr)	2018-03-29	2019-10-03	Pfizer Inc.	Variants de lfa3, compositions et utilisations associées
US10633458B2 (en)	2018-04-10	2020-04-28	Y-Biologics Inc.	Cell engaging binding molecules
CN112165974B (zh)	2018-05-31	2024-11-08	诺华股份有限公司	乙型肝炎抗体
PE20210320A1 (es)	2018-06-01	2021-02-16	Novartis Ag	Moleculas de union contra bcma y usos de las mismas
EP3824287A1 (fr)	2018-07-20	2021-05-26	Pierre Fabre Médicament	Récepteur pour vista
MX2021002690A (es)	2018-09-07	2021-05-12	Pfizer	Anticuerpos anti-avb8 y composiciones y usos de los mismos.
WO2020053742A2 (fr)	2018-09-10	2020-03-19	Novartis Ag	Anticorps peptidiques anti-hla-vhb
TW202028237A (zh)	2018-09-27	2020-08-01	美商西建公司	SIRPα結合蛋白及其使用方法
KR20210080386A (ko) *	2018-10-12	2021-06-30	유니버시티 오브 워싱턴	환자의 신체로부터 요독소를 제거하기 위한 시스템 및 방법
TW202039554A (zh)	2018-12-19	2020-11-01	瑞士商諾華公司	抗ＴＮＦ－α抗體
CA3234463A1 (fr)	2018-12-21	2019-12-18	Novartis Ag	Anticorps diriges contre pmel17 et conjugues de ces derniers
AU2020234394B2 (en)	2019-03-08	2024-02-15	AbTis Co., Ltd.	Site-specific antibody conjugation and antibody-drug conjugate as specific example thereof
TW202102526A (zh)	2019-04-04	2021-01-16	美商銳進科斯生物股份有限公司	重組腺相關病毒及其用途
WO2021021661A1 (fr)	2019-07-26	2021-02-04	Regenxbio Inc.	Élément régulateur d'acide nucléique modifié et ses procédés d'utilisation
WO2021062323A1 (fr)	2019-09-26	2021-04-01	Stcube & Co.	Anticorps spécifiques dirigés contre ctla-4 glycosylée et leurs procédés d'utilisation
EP4041768A1 (fr)	2019-10-09	2022-08-17	StCube & Co.	Anticorps spécifiques de lag3 glycosylé et leurs procédés d'utilisation
US20230203191A1 (en)	2020-03-30	2023-06-29	Danisco Us Inc	Engineered antibodies
WO2021202463A1 (fr)	2020-03-30	2021-10-07	Danisco Us Inc	Anticorps anti-rsv
US20230181756A1 (en)	2020-04-30	2023-06-15	Novartis Ag	Ccr7 antibody drug conjugates for treating cancer
CN116096758A (zh)	2020-05-01	2023-05-09	诺华股份有限公司	工程化免疫球蛋白
WO2021220218A1 (fr)	2020-05-01	2021-11-04	Novartis Ag	Variants d'immunoglobuline
EP4168433A4 (fr)	2020-06-17	2024-07-17	Janssen Biotech Inc	Matériels et méthodes pour la fabrication de cellules souches pluripotentes
CA3190174A1 (fr)	2020-08-03	2022-02-10	Janssen Biotech, Inc.	Materiaux et procedes pour le biotransport multidirectionnel dans des agents virotherapeutiques
KR102228138B1 (ko) *	2020-08-11	2021-03-17	(주)바이오제닉스	향 오일을 포함하는 마이크로캡슐의 제조방법, 이의 방법으로 제조된 향 오일을 함유하는 마이크로캡슐 및 이를 포함하는 분산액
US20230381341A1 (en)	2020-10-07	2023-11-30	Regenxbio Inc.	Adeno-associated viruses for ocular delivery of gene therapy
WO2022076750A2 (fr)	2020-10-07	2022-04-14	Regenxbio Inc.	Virus adéno-associés recombinants pour administration musculaire ou dans le snc
CN116472288A (zh)	2020-11-06	2023-07-21	诺华股份有限公司	抗体Fc变体
KR20230104651A (ko)	2020-11-06	2023-07-10	노파르티스 아게	Cd19 결합 분자 및 이의 용도
JP2023547506A (ja)	2020-11-06	2023-11-10	ノバルティスアーゲー	Ｂ細胞悪性腫瘍を治療するための抗ｃｄ１９剤及びｂ細胞標的化剤の組み合わせ療法
JP2024502832A (ja)	2020-12-31	2024-01-23	アラマーバイオサイエンシーズ，インコーポレイテッド	高親和性及び／または特異性を有する結合剤分子ならびにその製造及び使用方法
UY39610A (es)	2021-01-20	2022-08-31	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr
EP4323526A1 (fr)	2021-04-16	2024-02-21	Novartis AG	Conjugués anticorps-médicament et leurs procédés de fabrication
CA3226019A1 (fr)	2021-07-20	2023-01-26	Ags Therapeutics Sas	Vesicules extracellulaires provenant de microalgues, leur preparation et leurs utilisations
EP4413018A1 (fr)	2021-10-07	2024-08-14	RegenxBio Inc.	Virus adéno-associés recombinants pour administration ciblée
WO2023060272A2 (fr)	2021-10-07	2023-04-13	Regenxbio Inc.	Virus adéno-associés recombinants pour administration tropique au snc
EP4423285A1 (fr)	2021-10-28	2024-09-04	RegenxBio Inc.	Éléments régulateurs d'acides nucléiques modifiés, procédés et utilisations de ceux-ci
CN118119642A (zh)	2021-10-28	2024-05-31	诺华股份有限公司	工程化Fc变体
EP4460517A1 (fr)	2022-01-07	2024-11-13	Johnson & Johnson Enterprise Innovation Inc.	Matériaux et procédés de protéines de liaison à il-1beta
WO2023144127A1 (fr)	2022-01-31	2023-08-03	Ags Therapeutics Sas	Vésicules extracellulaires provenant de microalgues, leur biodistribution suite à leur administration, et leurs utilisations
AU2023217968A1 (en)	2022-02-09	2024-09-26	Janssen Biotech, Inc.	Methods and compositions comprising v beta 17 bispecific t cell engagers and bioengineered virus specific lymphocytes
TW202346590A (zh)	2022-03-13	2023-12-01	美商銳進科斯生物股份有限公司	經修飾之肌肉特異性啟動子
WO2023201277A1 (fr)	2022-04-14	2023-10-19	Regenxbio Inc.	Virus adéno-associés recombinants pour administration tropique au snc
WO2023201308A1 (fr)	2022-04-14	2023-10-19	Regenxbio Inc.	Thérapie génique pour le traitement d'une maladie oculaire
WO2023205610A2 (fr)	2022-04-18	2023-10-26	Regenxbio Inc.	Capsides aav hybrides
TW202400658A (zh)	2022-04-26	2024-01-01	瑞士商諾華公司	靶向ｉｌ—１３和ｉｌ—１８的多特異性抗體
WO2023232976A1 (fr)	2022-06-03	2023-12-07	Ags Therapeutics Sas	Vésicules extracellulaires provenant de microalgues génétiquement modifiées contenant une cargaison chargée de manière endogène, leur préparation et utilisations
WO2024013727A1 (fr)	2022-07-15	2024-01-18	Janssen Biotech, Inc.	Matériau et procédés d'appariement amélioré par génie biologique de régions variables de liaison à l'antigène
WO2024018426A1 (fr)	2022-07-22	2024-01-25	Janssen Biotech, Inc.	Transfert amélioré d'instructions génétiques à des cellules immunitaires effectrices
WO2024028732A1 (fr)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Constructions de liaison à cd98 pour le traitement de tumeurs cérébrales
WO2024028731A1 (fr)	2022-08-05	2024-02-08	Janssen Biotech, Inc.	Protéines de liaison de récepteur de transferrine pour traitement de tumeurs cérébrales
WO2024044725A2 (fr)	2022-08-24	2024-02-29	Regenxbio Inc.	Virus adéno-associés recombinants et leurs utilisations
WO2024081746A2 (fr)	2022-10-11	2024-04-18	Regenxbio Inc.	Éléments régulateurs d'acides nucléiques modifiés, méthodes et utilisations de ceux-ci
WO2024088808A1 (fr)	2022-10-24	2024-05-02	Ags Therapeutics Sas	Vésicules extracellulaires provenant de microalgues, leur biodistribution lors d'une administration intranasale, et leurs utilisations
WO2024182767A1 (fr)	2023-03-01	2024-09-06	Provention Bio, Inc.	Méthodes et compositions pour le traitement du diabète de type 1 comprenant du teplizumab et du vérapamil
WO2024194423A1 (fr)	2023-03-23	2024-09-26	Ags Therapeutics Sas	Vésicules extracellulaires de microalgues, et leur utilisation pour des vaccins et pour l'immunomodulation
WO2024206739A1 (fr)	2023-03-30	2024-10-03	Provention Bio, Inc.	Procédés de réduction de l'utilisation d'insuline exogène
WO2024216244A2 (fr)	2023-04-13	2024-10-17	Regenxbio Inc.	Ciblage de capsides d'aav, méthodes de fabrication et d'utilisation de ceux-ci

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4166800A (en)	1977-08-25	1979-09-04	Sandoz, Inc.	Processes for preparation of microspheres
US4384975A (en) *	1980-06-13	1983-05-24	Sandoz, Inc.	Process for preparation of microspheres
US4675189A (en)	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
PH19942A (en)	1980-11-18	1986-08-14	Sintex Inc	Microencapsulation of water soluble polypeptides
JPS60100516A (ja) *	1983-11-04	1985-06-04	Takeda Chem Ind Ltd	徐放型マイクロカプセルの製造法
US4568559A (en)	1984-02-06	1986-02-04	Biotek, Inc.	Composite core coated microparticles and process of preparing same
CH660302A5 (fr)	1984-10-17	1987-04-15	Debiopharm Sa	Procede de micro-encapsulation en phase heterogene de substances medicamenteuses hydrosolubles.
SE459005B (sv) *	1985-07-12	1989-05-29	Aake Rikard Lindahl	Saett att framstaella sfaeriska polymerpartiklar
US5000886A (en)	1987-05-26	1991-03-19	American Cyanamid Company	Silicone-hardened pharmaceutical microcapsules and process of making the same
US5019400A (en)	1989-05-01	1991-05-28	Enzytech, Inc.	Very low temperature casting of controlled release microspheres
AU5741590A (en) *	1989-05-04	1990-11-29	Southern Research Institute	Improved encapsulation process and products therefrom
SE9302777D0 (sv) *	1993-08-27	1993-08-27	Astra Ab	Process for conditioning substances
EP0674506B1 (fr)	1992-12-02	2000-08-23	Alkermes Controlled Therapeutics, Inc.	Microspheres contenant une hormone de croissance a liberation regulee
WO1994019020A1 (fr)	1993-02-23	1994-09-01	Genentech, Inc.	Stabilisation de polypeptides traites avec des solvants organiques au moyen d'excipients
ATE163230T1 (de)	1993-03-09	1998-02-15	Epic Therapeutics Inc	Makromolekulare mikropartikel und verfahren zu ihrer herstellung
DE69519382T3 (de)	1994-09-09	2008-09-18	Takeda Pharmaceutical Co. Ltd.	Zubereitung mit verzögerter freigabe eines metallsalz eines peptids
AU705968B2 (en)	1995-06-07	1999-06-03	Alkermes Controlled Therapeutics, Inc.	Device for releasing aggregation-stabilized, biologically active agent

1997
- 1997-10-23 SE SE9703874A patent/SE512663C2/sv not_active IP Right Cessation
1998
- 1998-09-24 AU AU94670/98A patent/AU732891B2/en not_active Ceased
- 1998-09-24 DE DE69818295T patent/DE69818295T2/de not_active Expired - Fee Related
- 1998-09-24 US US09/529,442 patent/US6861064B1/en not_active Expired - Fee Related
- 1998-09-24 PT PT98948005T patent/PT1033973E/pt unknown
- 1998-09-24 AT AT98948005T patent/ATE249813T1/de not_active IP Right Cessation
- 1998-09-24 JP JP2000516653A patent/JP2001520186A/ja active Pending
- 1998-09-24 DK DK98948005T patent/DK1033973T3/da active
- 1998-09-24 ES ES98948005T patent/ES2205551T3/es not_active Expired - Lifetime
- 1998-09-24 EP EP98948005A patent/EP1033973B1/fr not_active Expired - Lifetime
- 1998-09-24 WO PCT/SE1998/001717 patent/WO1999020253A1/fr active IP Right Grant
- 1998-09-24 HU HU0004732A patent/HU224008B1/hu active IP Right Grant
- 1998-09-24 CA CA002306824A patent/CA2306824C/fr not_active Expired - Fee Related
- 1998-09-24 IL IL13573398A patent/IL135733A/xx not_active IP Right Cessation
- 1998-09-24 KR KR1020007004276A patent/KR100572711B1/ko not_active IP Right Cessation
- 1998-09-24 CZ CZ20001352A patent/CZ299100B6/cs not_active IP Right Cessation
- 1998-10-08 ZA ZA989199A patent/ZA989199B/xx unknown
2000
- 2000-04-18 NO NO20002039A patent/NO310177B1/no unknown
2001
- 2001-02-02 HK HK01100785A patent/HK1029931A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
IL135733A (en)	2005-11-20
HU224008B1 (hu)	2005-04-28
CZ20001352A3 (cs)	2000-10-11
PT1033973E (pt)	2004-02-27
DE69818295T2 (de)	2004-07-08
KR20010031289A (ko)	2001-04-16
HUP0004732A2 (hu)	2001-05-28
EP1033973A1 (fr)	2000-09-13
JP2001520186A (ja)	2001-10-30
AU732891B2 (en)	2001-05-03
ZA989199B (en)	1999-04-15
US6861064B1 (en)	2005-03-01
HK1029931A1 (en)	2001-04-20
KR100572711B1 (ko)	2006-04-24
NO20002039D0 (no)	2000-04-18
NO20002039L (no)	2000-06-13
SE512663C2 (sv)	2000-04-17
CA2306824C (fr)	2008-01-08
AU9467098A (en)	1999-05-10
SE9703874D0 (sv)	1997-10-23
CZ299100B6 (cs)	2008-04-23
ES2205551T3 (es)	2004-05-01
EP1033973B1 (fr)	2003-09-17
DE69818295D1 (de)	2003-10-23
DK1033973T3 (da)	2004-02-02
WO1999020253A1 (fr)	1999-04-29
ATE249813T1 (de)	2003-10-15
IL135733A0 (en)	2001-05-20
HUP0004732A3 (en)	2001-12-28
CA2306824A1 (fr)	1999-04-29
SE9703874L (sv)	1999-04-24

Publication	Publication Date	Title
NO310177B1 (no)	2001-06-05	Fremgangsmåte for å innkapsle en aktiv substans samt vedvarende frigivelsesmikro- eller nanopartikler
CA2432904C (fr)	2007-09-11	Methode d'induction a changement de phase permettant de produire des microparticules contenant des agents actifs hydrophobes
AU769951B2 (en)	2004-02-12	Emulsion-based processes for making microparticles
EP0737472A1 (fr)	1996-10-16	Formulation de vaccin pour une administration unique
EP1187602A1 (fr)	2002-03-20	Composition pharmaceutique injectable a liberation durable et procedes de preparation de celle-ci
KR20180130344A (ko)	2018-12-07	미립구 제조방법 및 이에 의해 제조된 미립구
Park et al.	2007	Microencapsulation technology
US20080233201A1 (en)	2008-09-25	Method for Preparing Calibrated Biodegradable Microspheres
NZ507190A (en)	2002-02-01	Incorporation of active substances in carrier matrixes wherein an emulsion is contacted with a fluid gas using an anti-solvent technique
WO2002058672A2 (fr)	2002-08-01	Microparticules de polymere biodegradable encapsulant une substance biologiquement active et formulations pharmaceutiques a liberation prolongee contenant lesdites particules
JP2004517146A (ja)	2004-06-10	生物活性物質カプセル化生分解性高分子の微粒子および該微粒子を含有する徐放性医薬配合物
JP3709808B2 (ja)	2005-10-26	マイクロスフェアの製法
Yeo et al.	2005	Recent advances in microencapsulation technology
JP2020535224A (ja)	2020-12-03	二重エマルション技術によるマイクロ粒子を調製する方法
WO2015150942A2 (fr)	2015-10-08	Procédé amélioré de préparation de microparticules
AU2002224721A1 (en)	2002-08-06	Microparticles of biodegradable polymer encapsulating a biologically active substance
MXPA00009914A (en)	2001-07-31	Incorporation of active substances in carrier matrixes